Melanoma cell-secreted soluble factor that stimulates ubiquitination and degradation of the interferon alpha receptor and attenuates its signaling

Pigment Cell and Melanoma Research

Volumn 23, Issue 6, 2010, Pages 838-840

  HuangFu, Wei Chun ^a   Qian, Juan ^a   Liu, Chengbao ^b   Rui, Hallgeir ^b   Fuchs, Serge Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; BETA INTERFERON; JANUS KINASE; STAT1 PROTEIN; STAT2 PROTEIN; UBIQUITIN PROTEIN LIGASE E3;

CELL SURFACE; DEGRADATION; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; LETTER; MELANOCYTE; MELANOMA; PROTEIN PHOSPHORYLATION; TUMOR VASCULARIZATION; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; CULTURE MEDIA, CONDITIONED; DOWN-REGULATION; HUMANS; INTERFERON-ALPHA; MELANOMA; NEOPLASM PROTEINS; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STAT1 TRANSCRIPTION FACTOR; UBIQUITINATION;

EID: 78049234828     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2010.00770.x     Document Type: Letter

References (11)

1. Ascierto, P.A., and Kirkwood, J.M. (2008). Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med, 6, 62.
2. Bhattacharya, S., Huangfu, W.C., Liu, J., Veeranki, S., Baker, D.P., Koumenis, C., Diehl, J.A., and Fuchs, S.Y. (2010). Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor. J. Biol. Chem., 285, 2318-2325.
3. Coccia, E.M., Uze, G., and Pellegrini, S. (2006). Negative regulation of type I interferon signaling: facts and mechanisms. Cell Mol Biol (Noisy-le-grand), 52, 77-87.
4. Kumar, K.G., Tang, W., Ravindranath, A.K., Clark, W.A., Croze, E., and Fuchs, S.Y. (2003). SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J., 22, 5480-5490.
5. Kumar, K.G., Krolewski, J.J., and Fuchs, S.Y. (2004). Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. J. Biol. Chem., 279, 46614-46620.
6. Kumar, K.G., Liu, J., Li, Y., Yu, D., Thomas-Tikhonenko, A., Herlyn, M., and Fuchs, S.Y. (2007). Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. Cancer Biol Ther, 6, 1437-1441.
7. Messina, J.L., Yu, H., Riker, A.I., Munster, P.N., Jove, R.L., and Daud, A.I. (2008). Activated stat-3 in melanoma. Cancer Control, 15, 196-201.
8. Mocellin, S., Pasquali, S., Rossi, C.R., and Nitti, D. (2010). Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J. Natl Cancer Inst., 102, 493-501.
9. Platanias, L.C. (2005). Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol., 5, 375-386.
10. Shih, I.M., and Herlyn, M. (1994). Autocrine and paracrine roles for growth factors in melanoma. In Vivo, 8, 113-123.
11. Spiegelman, V.S., Tang, W., Chan, A.M., Igarashi, M., Aaronson, S.A., Sassoon, D.A., Katoh, M., Slaga, T.J., and Fuchs, S.Y. (2002). Induction of homologue of Slimb ubiquitin ligase receptor by mitogen signaling. J. Biol. Chem., 277, 36624-36630.